ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

Estradiol

Also written as “NOMAC-E2”, “estradiol, 25 mcg” and “estradiol, 10 mcg”.

Its studies are mostly in Hot Flashes · Dyspareunia · Atrophic Vaginitis · Leiomyoma · Menorrhagia, led by 21 companies.

Drug pageEstradiol: every studyMany companies study it; this page follows only the 55 they lead. All 300 studies, academic ones too, with its approvals and label.
Furthest: phase 4, since Oct 8, 201255 company-led studies, 1 open or runningNext primary completion: May 31, 2027 (phase 1)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Novo Nordiskits history only120 open or runningphase 4since Oct 8, 2012Apr 19, 2005none ahead
Bayerits history only100 open or runningphase 4since Sep 12, 2005Sep 9, 2005none ahead
AbbVie80 open or runningphase 3since Feb 17, 2010Feb 17, 2010none ahead
Teva Pharmaceutical Industriesits history only30 open or runningphase 3since Nov 7, 2022Jul 2, 2010none ahead
TherapeuticsMDits history only30 open or runningphase 3since Sep 5, 2013Sep 5, 2013none ahead
Grünenthalits history only20 open or runningphase 1since Nov 9, 2018Nov 9, 2018none ahead
Merckits history only20 open or runningphase 1since Nov 26, 2008Nov 26, 2008none ahead
Renovoits history only20 open or runningphase 3since Jan 24, 2007Jan 24, 2007none ahead
Amneal Pharmaceuticalsits history only10 open or runningphase 3since Jan 28, 2013Jan 28, 2013none ahead
ASCEND Therapeuticsits history only10 open or runningphase 4since Sep 8, 2005Sep 8, 2005none ahead

Also a collaborator on its studies: IQVIA Pty, Abbott, Simbec Research, Laboratoires Besins International and Grünenthal.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of AbbVie only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Feb 17, 2010First study: phase 3 study in Hormone Replacement TherapyFirst studyNCT01070979 · 249 enrolled · United States
  2. Jul 20, 2011Phase 3 study in Postmenopausal Vulvovaginal AtrophyNCT01400776 · 722 enrolled · United States
  3. Oct 17, 2011Phase 3 study in Vulvovaginal AtrophyNCT01455597 · 309 enrolled · United States
  4. Apr 25, 2013Phase 3 study in DyspareuniaNCT01845649 · 550 enrolled · United States
  5. Jan 8, 2016Phase 3 study in LeiomyomaNCT02654054 · 413 enrolled · United States, Canada, Puerto Rico
  6. Feb 22, 2016Phase 3 study in LeiomyomaNCT02691494 · 378 enrolled · United States, Canada
  7. Jul 7, 2017Phase 3 study in EndometriosisNCT03213457 · 681 enrolled · United States, Canada, Puerto Rico
  8. Aug 31, 2017Phase 3 study in MenorrhagiaNCT03271489 · 478 enrolled · United States, Puerto Rico

TargetBeta

ESR1 →read by rule
“Estrogen receptor alpha agonist”ChEMBL 37, by rule

Other programs on ESR1

ProgramCompanyFurthest phaseStudies
Ethinyl EstradiolruleJohnson & Johnsonphase 470
FulvestrantruleAstraZenecaphase 430
TamoxifenruleAstraZenecaphase 421
ClomipheneruleHamad Medicalphase 43
vepdegestrantrulePfizerphase 320
camizestrantruleAstraZenecaphase 318
giredestrantHoffmann-La Rochephase 317
HRS-8080Jiangsu HengRui Medicinephase 313
elacestrantruleMenarini Groupphase 312
ImlunestrantruleEli Lillyphase 312
taragarestrantruleInventisBiophase 35
SIM0270ruleSimcere Pharmaceutical Groupphase 35

Studies

All 8 AbbVie leads, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT03271489Menorrhagia · United States, Puerto Rico3CompletedJun 28, 2024478
NCT03213457Endometriosis · United States, Canada, Puerto Rico3CompletedMar 27, 2020681
NCT02691494Leiomyoma · United States, Canada3CompletedFeb 14, 2018378
NCT02654054Leiomyoma · United States, Canada, Puerto Rico3CompletedJan 18, 2018413
NCT01845649Dyspareunia · United States3CompletedNov 20, 2013550
NCT01455597Vulvovaginal Atrophy · United States3CompletedDec 3, 2012309
NCT01400776Postmenopausal Vulvovaginal Atrophy · United States3CompletedFeb 27, 2012722
NCT01070979Hormone Replacement Therapy · United States3CompletedSep 2003249

How it is read

Names in the registry

  • “Estradiol”, 7 entries
  • “NOMAC-E2”, 6 entries
  • “estradiol, 25 mcg”, 5 entries
  • “estradiol, 10 mcg”, 4 entries
  • “Zesteem”, 4 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.